Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification.
Trizuljak J, Sperr WR, Nekvindová L, Elberink HO, Gleixner KV, Gorska A, Lange M, Hartmann K, Illerhaus A, Bonifacio M, Perkins C, Elena C, Malcovati L, Fortina AB, Shoumariyeh K, Jawhar M, Zanotti R, Bonadonna P, Caroppo F, Zink A, Triggiani M, Parente R, von Bubnoff N, Yavuz AS, Hägglund H, Mattsson M, Panse J, Jäkel N, Kilbertus A, Hermine O, Arock M, Fuchs D, Sabato V, Brockow K, Bretterklieber A, Niedoszytko M, van Anrooij B, Reiter A, Gotlib J, Kluin-Nelemans HC, Mayer J, Doubek M, Valent P. Trizuljak J, et al. Among authors: jakel n. Allergy. 2020 Aug;75(8):1927-1938. doi: 10.1111/all.14248. Epub 2020 Mar 16. Allergy. 2020. PMID: 32108361 Free PMC article.
Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Competence Network on Mastocytosis.
Aberer E, Sperr WR, Bretterklieber A, Avian A, Hadzijusufovic E, Kluin-Nelemans HC, Oude Elberink H, van Anrooij B, Niedoszytko M, Lange M, Górska A, Elena C, Brazzelli V, Belloni Fortina A, Caroppo F, Hartmann K, Illerhaus A, Reiter A, Jawhar M, Bonadonna P, Zanotti R, Triggiani M, Parente R, Gotlib J, Doubek M, von Bubnoff N, Fuchs D, Sabato V, Brockow K, Jäkel N, Panse J, Valent P. Aberer E, et al. Among authors: jakel n. J Invest Dermatol. 2021 Jul;141(7):1719-1727. doi: 10.1016/j.jid.2020.12.030. Epub 2021 Feb 11. J Invest Dermatol. 2021. PMID: 33581142 Free article.
Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077.
Pönisch W, Heyn S, Beck J, Wagner I, Mohren M, Hoffmann FA, Lange T, Schmalfeld M, Zehrfeld T, Schwarzer A, Winkelmann C, Edelmann T, Röhrborn R, Hebenstreit K, Al-Ali HK, Jäkel N, Niederwieser D. Pönisch W, et al. Among authors: jakel n. Br J Haematol. 2013 Jul;162(2):202-9. doi: 10.1111/bjh.12361. Epub 2013 May 21. Br J Haematol. 2013. PMID: 23692564 Free article. Clinical Trial.
Prospective phase II study of preemptive chimerism-driven reduction of immunosuppression after non-myeloablative conditioning-Eudract #: 2007-002420-15.
Hell S, Jentzsch M, Franke GN, Jäkel N, Schulze S, Edelmann J, Nenoff K, Grieb N, Jeremic V, Cross M, Leiblein S, Bach E, Pönisch W, Al-Ali HK, Schwind S, Platzbecker U, Lange T, Niederwieser D, Vucinic V. Hell S, et al. Among authors: jakel n. Bone Marrow Transplant. 2022 May;57(5):824-826. doi: 10.1038/s41409-022-01609-6. Epub 2022 Feb 18. Bone Marrow Transplant. 2022. PMID: 35181744 Free PMC article. Clinical Trial. No abstract available.
Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma.
Pönisch W, Bourgeois M, Moll B, Heyn S, Jäkel N, Wagner I, Rohrberg R, Hurtz HJ, Schmalfeld M, Aßmann M, Edelmann T, Mohren M, Hoffmann FA, Becker C, Schwarzer A, Schönfelder U, Zehrfeld T, Hensel G, Löschcke K, Krahl R, Ali HA, Niederwieser D. Pönisch W, et al. Among authors: jakel n. J Cancer Res Clin Oncol. 2013 Mar;139(3):499-508. doi: 10.1007/s00432-012-1339-3. Epub 2012 Nov 25. J Cancer Res Clin Oncol. 2013. PMID: 23184429
The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis.
McMullin MF, Harrison CN, Niederwieser D, Demuynck H, Jäkel N, Gopalakrishna P, McQuitty M, Stalbovskaya V, Recher C, Theunissen K, Gisslinger H, Kiladjian JJ, Al-Ali HK. McMullin MF, et al. Among authors: jakel n. Exp Hematol Oncol. 2015 Sep 15;4:26. doi: 10.1186/s40164-015-0021-2. eCollection 2015. Exp Hematol Oncol. 2015. PMID: 26380150 Free PMC article.
15 results